University of Texas at El Paso

ScholarWorks@UTEP
Departmental Technical Reports (CS)

Computer Science

7-2020

COVID-19 Peak Immunity Values Seem to Follow Lognormal
Distribution
Julio Urenda
The University of Texas at El Paso, jcurenda@utep.edu

Olga Kosheleva
The University of Texas at El Paso, olgak@utep.edu

Vladik Kreinovich
The University of Texas at El Paso, vladik@utep.edu

Tonghui Wang
New Mexico State University - Main Campus, twang@nmsu.edu

Follow this and additional works at: https://scholarworks.utep.edu/cs_techrep
Part of the Applied Mathematics Commons, and the Public Health Commons

Comments:
Technical Report: UTEP-CS-20-79
Recommended Citation
Urenda, Julio; Kosheleva, Olga; Kreinovich, Vladik; and Wang, Tonghui, "COVID-19 Peak Immunity Values
Seem to Follow Lognormal Distribution" (2020). Departmental Technical Reports (CS). 1485.
https://scholarworks.utep.edu/cs_techrep/1485

This Article is brought to you for free and open access by the Computer Science at ScholarWorks@UTEP. It has
been accepted for inclusion in Departmental Technical Reports (CS) by an authorized administrator of
ScholarWorks@UTEP. For more information, please contact lweber@utep.edu.

COVID-19 Peak Immunity Values Seem to
Follow Lognormal Distribution
Julio Urenda1,2 , Olga Kosheleva3 ,
Vladik Kreinovich2 , and Tonghui Wang4
1
Department of Mathematical Sciences
2
Department of Computer Science
3
Department of Teacher Education
University of Texas at El Paso
El Passo, TX 79968, USA
jcurenda@utep.edu. olgak@utep.edu, vladik@utep.edu
4
Department of Mathematical Sciences
New Mexico State University
Las Cruces, NM 88003, USA
twang@nmsu.edu
Abstract
For the current pandemic, an important open problem is immunity:
do people who had this disease become immune against further infections?
In the immunity study, it is important to know how frequent are different
levels of immunity, i.e., what is the probability distribution of the immunity levels. Different people have different rates of immunity dynamics:
for some, immunity gets to the level faster, for others the immunity effect
is slower. Similarly, in some patients, immunity stays longer, it others,
it decreases faster. In view of this, an important characteristic is peak
immunity. A recent study provides some statistics on the peak immunity.
There is not enough data to provide a statistically guaranteed selection
of a probability distribution, but we can already make some preliminary
conclusions. Specifically, based on the available data, we argue that the
COVID-19 peak immunity values follow lognormal distribution.

1

Formulation of the Problem

Immunity studies are important. In an epidemic, some people have a mild
version of the disease, some have a strong (or even deadly version). Usually,
recovered people gain an immunity, meaning that they cannot be infected again
– at least for some time.
For some diseases, vaccines are available that induce immunity.
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Once the majority of people gain immunity, the epidemic slows down and
stops.
Immunity question is especially important for COVID-19. For the
current epidemic, no vaccine is available yet. So, to predict the further dynamics
of the epidemic – and to develop methods to decrease its spread – it is very
important to study the levels of immunity of people who recovered from this
disease.
COVID-19 immunity study. The results of studying immunity of patients
who recovered from COVID-19 have recently appeared in the paper [1].
The resulting data. In this study, the immunity level of each patient was
studied for a 3-month period. For each patient, an important characteristic is
the peak immunity level. After the peak, this level starts decreasing, but the
peak level usually indicates how strong will the immunity response become if
the body encounters the same disease.
Different patients have different peak immunity level. The paper [1] provides
the following information about the number of patients with different peak immunity levels (as measured in appropriate units):
• 3.1% of the patients have peak immunity level below 50;
• 7.7% of the patients have peak immunity level between 50 and 200;
• 10.8% of the patients have peak immunity level between 200 and 500;
• 18.5% of the patients have peak immunity level between 500 and 2000;
and
• 60% of the patients have peak immunity level above 2000.
So what is the corresponding distribution? To study the disease, it is
important to know how many people have different immunity level, i.e., it is
important to know the probability distribution of the peak immunity level.
What we do in this paper. The above data provides, in effect, four independent observations – the fifth number is simply 100% minus the sum of the first
four values. Of course, it is not enough to have four observations to determine
the probability distribution with a statistical guarantee. To get a guaranteed
conclusion, we need to wait until more studies are done.
However, some answers are needed right away. So, what we do is provide
a reasonable hypothesis about this distribution – a hypothesis that lead to
lognormal distribution, and then we show that the above empirical data is indeed
in very good accordance with this distribution.
Comment. It is important to notice that for each moment of time, the actual
distribution of immunity is more complex. For example, the distribution for days
40-50 after the onset of symptoms is clearly bimodal [1]. This complexity can
be explained by the fact that different people have different rates of immunity
change. So:
2

• when we compare the peak immunity values, we get a meaningful distributions, but
• when we compare values at a given intermediate moment of time, we bring
together patients at different stages of the immunity dynamics, as a result
we get a more complex distribution – probably a convex combination of
several log-normal distributions corresponding to different rates.
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Analysis of the Problem and the Resulting
Hypothesis

Analysis of the problem. Usually, immunity to a disease is affected by many
different factors. Factors such as general physical fitness, body-mass index,
age, etc., can drastically increase or decrease immunity level. This increase
of decrease is usually expressed in percent terms: e.g., a typical statement is
“regular physical activities increase immunity by 20%”. This means that each
of the immunity-affecting factors multiplies the average immunity level by a
certain constant – a constant which is larger than 1 is it is an increase, and a
constant which is smaller than 1 if it is a decrease.
Thus, to find the joint effect of several factors, we need to multiply the
average immunity level by all these factors. Thus, the resulting immunity level
is a product of several constants corresponding to different factors.
Each of these constants varies from one person to another, so it can be viewed
as a random variable. Constants corresponding to different factors are usually
independent: e.g., some young people are physically active some are not, same
with older people. So, the immunity level is the product of many independent
random variables.
What is the resulting distribution? Situations when we have a product
of many independent random variables may not be standard in statistics, but
we can easily reduce this situation to a more convenient one if we take the
logarithm of the immunity level. It is well known that the logarithm of the
product is equal to the sum of the logarithm. Thus, the logarithm of the peak
immunity level is the sum of a large number of independent random variables –
logarithms of the corresponding constants.
It is known that under reasonable conditions, the sum of a large number n of
independent random variables tends to the normal (Gaussian) distribution; this
is known as the Central Limit Theorem; see, e.g., [2]. This means that when
the value n is large, the corresponding distribution is close to Gaussian. This is
the reason why normal distributions are ubiquitous.
In our case, we can therefore conclude that the logarithm X = ln(Y ) of the
peak immunity level Y is normally distributed – and thus, that the distribution
of the peak immunity level Y itself is log-normal.
Let us see if this conclusion is consistent with the above data.
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Empirical Data Is in Good Accordance with
the Log-Normal Distribution

Let us convert the data into cumulative distribution function values. Probability distributions are usually described in terms of cumulative
distribution function (cdf) or in terms of the probability density function (pdf).
def

The above distribution is the easiest to describe in terms of the cdf FY (y) =
Prob (Y ≤ y):
• for y = 50, the probability is
FY (50) = 3.1%;
• for y = 200, the probability is
FY (200) = 3.1% + 7.7% = 10.8%;
• for y = 500, the probability is
FY (500) = 3.1% + 7.7% + 10.8% = 21.6%;
and
• for y = 2000, the probability is
FY (2000) = 3.1% + 7.7% + 10.8% + 18.5% = 40.1%.

Log-normal distribution: a brief reminder. A random variable Y is said
def
to have a log-normal distribution with parameters µ and σ if X = ln(Y ) is
normally distributed with mean µ and standard deviation σ; this is usually
denoted as X ∼ N (µ, σ 2 ). Let Φ(t) denote the cdf and the pdf of the N (0, 1)
distribution. Then the pdf of Y is given by


1
(ln y − µ)2
1
,
(1)
fY (y) = · √ · exp −
y σ 2π
2σ 2
where ln(y) is the natural logarithm of y, and the cdf of Y has the form:


ln(y) − µ
def
FY (y) = Prob (Y ≤ y) = Φ
.
σ

(2)

Let us go to logarithms. In view of the definition of log-normal distribution
– and of the fact that normal distributions are ubiquitous and, as a result, there
exists many tests of normality – it is reasonable to test that ln(Y ) is normally
distributed.
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The original definition of the log-normal distribution says that the natural
logarithm of Y is normal. For our data, as we will see, it is more convenient to
ln(Y )
use decimal logarithms log10 (x). Since log10 (Y ) =
, natural logarithm is
ln(10)
normally distributed if and only the decimal logarithm is.
So, let us use decimal logarithms. It is well know that
210 = 1024 ≈ 103 = 1000,
thus, log10 (2) ≈ 0.3. Hence,
log10 (5) = log10 (10/2) = log10 (10) − log10 (2) ≈ 0.7,
so we conclude that
log10 (50) ≈ 1.7, log10 (200) ≈ 2.3, log10 (500) ≈ 2.7, log10 (2000) ≈ 3.3.
Thus, for X = ln(Y ), the corresponding pdf FX (x) = Prob (X ≤ x) has the
following form:
• for x = 1.7, the probability is FX (1.7) = 3.1%;
• for x = 2.3, the probability is FX (2.3) = 10.8%;
• for x = 2.7, the probability is FX (2.7) = 21.6%; and
• for x = 3.3, the probability is FX (3.3) = 40.1%.
Let us prepare for checking that the empirical distribution for X =
log(Y ) is normal. If we know the value p = Φ(t), we can determine the
corresponding value t as t = Φ−1 (p), where Φ−1 (p) denotes the inverse function
of Φ(t).
For a general normal distribution X, with mean µ and standard deviation
X −µ
is normally distributed with mean 0 and standard
σ, the expression
σ


x−µ
. Thus, if we know the value p = FX (x),
deviation 1. So, FX (x) = Φ
σ
x−µ
we can conclude that
= Φ−1 (p) and thus, that x = µ + σ · Φ−1 (p).
σ
Based on the tables of the function Φ(t), we conclude that:
Φ−1 (0.031) ≈ −1.86,

Φ−1 (0.108) ≈ −1.27,

Φ−1 (0.216) ≈ −0.79,

Φ−1 (0.401) ≈ −0.25.

Thus, the above four points lead to the following four equations:
µ − 1.86 σ ≈ 1.7;

(3)

µ − 1.27 σ ≈ 2.3;

(4)

µ − 0.79 σ ≈ 2.7;

(5)

µ − 0.25 σ ≈ 3.3.

(6)
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How can we check: first idea. We have four equations that bind two parameters µ and σ. In principle, we can determine µ and σ, e.g., from the first two
equations, and see if the resulting values fit the other two formulas. One fit may
be a coincidence, but two fits would be a good argument that the distribution
is actually log-normal.
Checking confirms log-normal character of the distribution of peak
immunity. Subtracting the first equation from the second one, we conclude
that 0.59σ ≈ 0.6, so σ ≈ 1.02. Thus, from the first equation, we can conclude
that
µ ≈ 1.7 + 1.86 · σ ≈ 1.7 + 1.86 · 1.02 ≈ 3.60.
Substituting the values µ ≈ 3.60 and σ ≈ 1.02 into the left-hand sides of the
formulas (3) and (4), we get:
µ − 0.79σ ≈ 3.60 − 0.79 · 1.02 ≈ 2.79
and
µ − 0.25σ ≈ 3.60 − 0.25 · 1.02 ≈ 3.24.
These are indeed good approximations to the observed values 2.7 and 3.3. So,
the data indeed seems to confirms the log-normal character of the distribution.
How we can check: second idea. Another possibility is to treat Equations (3)–(6) as a regression model; see, e.g., [2]. In this case, the least squares
estimates of µ and σ are
µ
b = 3.588

and

σ
b = 1.018,

with the R squared value equal to R2 = 0.997.
This also confirms that the data is consistent with log-normal distribution.
Comment. This may seem convincing, but it is worth reminding that we only
have four data points, not enough to make a statistically convincing conclusion.
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